Literature DB >> 21615538

Optimising absorption of posaconazole.

Myke R Green1, Joseph E Woolery.   

Abstract

Posaconazole, a triazole antifungal agent with proven efficacy for prophylaxis and treatment of fungal infections, is often limited by poor absorption. We report on five consecutive patients who received posaconazole along with a care bundle intended to increase absorption by addressing gastric pH, co-administration with food, dividing doses and avoiding drug interactions. Each patient yielded multiple robust posaconazole serum concentrations. No patient experienced breakthrough fungal infection while receiving posaconazole. The posaconazole care bundle administered to oncology patients is feasible and may optimise posaconazole absorption.
© 2011 Blackwell Verlag GmbH.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21615538     DOI: 10.1111/j.1439-0507.2011.02020.x

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  4 in total

1.  Antifungal prophylaxis with posaconazole in patients with acute myeloid leukemia: dose intensification coupled with avoidance of proton pump inhibitors is beneficial in shortening time to effective concentrations.

Authors:  Piergiorgio Cojutti; Anna Candoni; Erica Simeone; Loretta Franceschi; Renato Fanin; Federico Pea
Journal:  Antimicrob Agents Chemother       Date:  2013-09-23       Impact factor: 5.191

2.  The Genetic Polymorphism UGT1A4*3 Is Associated with Low Posaconazole Plasma Concentrations in Hematological Malignancy Patients Receiving the Oral Suspension.

Authors:  Hyeon Jeong Suh; Seo Hyun Yoon; Kyung-Sang Yu; Joo-Youn Cho; Sang-In Park; Eunyoung Lee; Jeong-Ok Lee; Youngil Koh; Kyoung-Ho Song; Pyoeng Gyun Choe; Eu Suk Kim; Soo-Mee Bang; Hong Bin Kim; Inho Kim; Nam Joong Kim; Sang Hoon Song; Wan Beom Park; Myoung-Don Oh
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

3.  Dried blood spot analysis suitable for therapeutic drug monitoring of voriconazole, fluconazole, and posaconazole.

Authors:  Kim C M van der Elst; Lambert F R Span; Kai van Hateren; Karin M Vermeulen; Tjip S van der Werf; Ben Greijdanus; Jos G W Kosterink; Donald R A Uges; Jan-Willem C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2013-07-29       Impact factor: 5.191

Review 4.  Multidisciplinary approach in diagnosis and treatment of COVID-19-associated mucormycosis: a description of current reports.

Authors:  Hyma Gogineni; Wonhee So; Kenneth Mata; John N Greene
Journal:  Egypt J Intern Med       Date:  2022-07-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.